scholarly journals Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet ◽  
2015 ◽  
Vol 386 (10008) ◽  
pp. 2078-2088 ◽  
Author(s):  
Cornelia L Trimble ◽  
Matthew P Morrow ◽  
Kimberly A Kraynyak ◽  
Xuefei Shen ◽  
Michael Dallas ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document